دورية أكاديمية
أعرض في EDS

Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.

التفاصيل البيبلوغرافية
العنوان: Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
المؤلفون: Yuan Q; Department of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, China., Ren J; Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China., Li L; Department of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, China., Li S; Department of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, China., Xiang K; Department of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, China., Shang D; Department of General Surgery, First Affiliated Hospital of Dalian Medical University, Dalian, China.; Clinical Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, China.
المصدر: Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 2432-2448.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Validation Study
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101581063 Publication Model: Print Cited Medium: Internet ISSN: 2165-5987 (Electronic) Linking ISSN: 21655979 NLM ISO Abbreviation: Bioengineered Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin : Landes Bioscience
مواضيع طبية MeSH: Gene Expression Profiling*, Adenocarcinoma/*genetics , Adenosine/*analogs & derivatives , Pancreatic Neoplasms/*genetics , RNA, Long Noncoding/*metabolism, Adenocarcinoma/immunology ; Adenocarcinoma/pathology ; Adenosine/metabolism ; Aged ; Cohort Studies ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Pancreatic Neoplasms/immunology ; Pancreatic Neoplasms/pathology ; Prognosis ; RNA, Long Noncoding/genetics ; Risk Factors ; Signal Transduction/genetics
مستخلص: Accumulating evidence has unveiled the pivotal roles of N6-methyladenosine (m6A) in pancreatic adenocarcinoma (PAAD). However, there are not many researches to predict the prognosis of PAAD using m6A-related long non-coding RNAs (lncRNAs). Raw data from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and the Genotype-Tissue Expression project (GTEx) were utilized to comprehensively analyze the expression and prognostic performances of 145 m6A-related lncRNAs in PAAD and to develop and validate a novel m6A-related multi-lncRNA prognostic signature (m6A-LPS) for PAAD patients. In total, 57 differentially expressed m6A-related lncRNAs with prognostic values were identified. Based on LASSO-Cox regression analysis, m6A-LPS was constructed and verified by using five-lncRNA expression profiles for TCGA and ICGC cohorts. PAAD patients were then divided into high- and low-risKBIE_A_1933868k subgroups with different clinical outcomes according to the median risk score; this was further verified by time-dependent receiver operating characteristic curves. Risk scores were significantly associated with clinical parameters such as histological grade and cancer status among PAAD patients. A nomogram consisting of risk score, grade, and cancer status was generated to predict the survival probability of PAAD patients, as also demonstrated by calibration curves. Discrepancies in cellular processes, signaling pathways, and immune status between the high- and low-risk subgroups were investigated by functional and single-sample gene set enrichment analyses. In conclusion, the novel m6A-LPS for PAAD patients was developed and validated, which might provide new insight into clinical decision-making and precision medicine.
References: Pathology. 2014 Aug;46(5):396-401. (PMID: 24977734)
Mol Cancer. 2020 Jan 6;19(1):3. (PMID: 31906946)
J Exp Clin Cancer Res. 2018 Dec 19;37(1):319. (PMID: 30567565)
Biomed Res Int. 2020 Oct 9;2020:3801748. (PMID: 33102579)
Nature. 2012 Apr 29;485(7397):201-6. (PMID: 22575960)
J Exp Clin Cancer Res. 2018 Jun 19;37(1):120. (PMID: 29921308)
Aging (Albany NY). 2019 Mar 15;11(6):1633-1647. (PMID: 30877265)
PeerJ. 2020 Sep 28;8:e9602. (PMID: 33062408)
Cancer Biol Med. 2013 Sep;10(3):138-41. (PMID: 24379988)
Oxid Med Cell Longev. 2020 Dec 28;2020:6634247. (PMID: 33425212)
Biosci Rep. 2019 Dec 20;39(12):. (PMID: 31808521)
Bioinformatics. 2012 Mar 15;28(6):882-3. (PMID: 22257669)
Front Oncol. 2020 Sep 14;10:1764. (PMID: 33042823)
Oncogene. 2020 Jun;39(23):4507-4518. (PMID: 32366907)
J Cancer. 2020 Mar 4;11(10):3027-3040. (PMID: 32226518)
Cell Death Dis. 2019 Sep 20;10(10):698. (PMID: 31541081)
Int J Epidemiol. 2015 Feb;44(1):186-98. (PMID: 25502106)
J Cell Biochem. 2019 Sep;120(9):14916-14927. (PMID: 31016791)
Genomics. 2020 May;112(3):2640-2646. (PMID: 32087243)
Front Cell Dev Biol. 2020 Jul 23;8:642. (PMID: 32793593)
Onco Targets Ther. 2017 Nov 02;10:5243-5254. (PMID: 29138577)
BMC Cancer. 2019 Aug 7;19(1):779. (PMID: 31391008)
Nat Rev Genet. 2014 May;15(5):293-306. (PMID: 24662220)
Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
Mol Ther Nucleic Acids. 2018 Sep 7;12:229-241. (PMID: 30195762)
Gut. 2020 Jul;69(7):1193-1205. (PMID: 31582403)
Cell Physiol Biochem. 2017;44(3):948-966. (PMID: 29179183)
J Acad Nutr Diet. 2018 Apr;118(4):555-567. (PMID: 28919082)
Cancer Cell Int. 2019 May 20;19:136. (PMID: 31139013)
Clin Cancer Res. 2006 Aug 15;12(16):4851-8. (PMID: 16914571)
J Cell Mol Med. 2020 Feb;24(3):2342-2355. (PMID: 31883309)
Hepatology. 2018 Jun;67(6):2254-2270. (PMID: 29171881)
Cancer Cell Int. 2020 Jun 11;20:231. (PMID: 32536819)
Mol Carcinog. 2018 May;57(5):590-597. (PMID: 29315835)
J Cancer. 2020 Feb 3;11(8):2150-2157. (PMID: 32127942)
Tumour Biol. 2017 Jun;39(6):1010428317709990. (PMID: 28639914)
Clin J Gastroenterol. 2019 Aug;12(4):285-291. (PMID: 30788774)
Gynecol Oncol. 2019 Dec;155(3):499-507. (PMID: 31662204)
J Cell Biochem. 2019 Jun;120(6):9034-9046. (PMID: 30582215)
J Genet. 2020;99:. (PMID: 32529986)
J Exp Clin Cancer Res. 2018 Sep 10;37(1):222. (PMID: 30201010)
Biochim Biophys Acta Gene Regul Mech. 2020 Apr;1863(4):194419. (PMID: 31487549)
Int J Biol Sci. 2020 Mar 25;16(11):1785-1797. (PMID: 32398949)
Front Genet. 2020 Dec 23;11:608668. (PMID: 33424932)
Int J Mol Sci. 2018 Feb 06;19(2):. (PMID: 29415429)
Ann Transl Med. 2020 Mar;8(6):387. (PMID: 32355831)
Int J Biol Sci. 2018 Jan 12;14(2):124-136. (PMID: 29483831)
Mol Cancer. 2018 May 24;17(1):92. (PMID: 29793547)
Biosci Rep. 2021 Apr 30;41(4):. (PMID: 33835133)
Cancer Med. 2020 Nov;9(22):8589-8599. (PMID: 32902196)
Int J Clin Exp Med. 2015 Nov 15;8(11):21854-60. (PMID: 26885155)
فهرسة مساهمة: Keywords: N6-methyladenosine; Pancreatic adenocarcinoma; bioinformatics; long non-coding RNAs; prognostic signature
المشرفين على المادة: 0 (RNA, Long Noncoding)
CLE6G00625 (N-methyladenosine)
K72T3FS567 (Adenosine)
تواريخ الأحداث: Date Created: 20210708 Date Completed: 20211111 Latest Revision: 20220204
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC8806915
DOI: 10.1080/21655979.2021.1933868
PMID: 34233576
قاعدة البيانات: MEDLINE
الوصف
تدمد:2165-5987
DOI:10.1080/21655979.2021.1933868